Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Crinetics Pharmaceuticals ( (CRNX) ) just unveiled an announcement.
On June 26, 2025, Crinetics Pharmaceuticals held a Research and Development Day in New York, presenting updates on its preclinical pipeline. Key highlights included the development of CRN12755 for Graves’ disease, CRN10329 for polycystic kidney disease, and CRN09682 for neuroendocrine tumors. The event showcased promising preclinical data and outlined strategic plans for clinical trials, indicating potential advancements in treatment options for these conditions.
The most recent analyst rating on (CRNX) stock is a Buy with a $62.00 price target. To see the full list of analyst forecasts on Crinetics Pharmaceuticals stock, see the CRNX Stock Forecast page.
Spark’s Take on CRNX Stock
According to Spark, TipRanks’ AI Analyst, CRNX is a Neutral.
Crinetics Pharmaceuticals exhibits significant financial challenges, impacting its overall score. While technical analysis and corporate events provide some positive insights, the negative valuation metrics and financial instability are major concerns. Strategic initiatives and a strong cash position offer potential future upside.
To see Spark’s full report on CRNX stock, click here.
More about Crinetics Pharmaceuticals
Crinetics Pharmaceuticals operates in the biotechnology industry, focusing on the development of therapies for endocrine disorders. The company is engaged in advancing its pipeline with products targeting conditions such as Graves’ disease, polycystic kidney disease, and neuroendocrine tumors, leveraging its expertise in peptide hormone GPCR pharmacology.
Average Trading Volume: 890,271
Technical Sentiment Signal: Sell
Current Market Cap: $2.85B
See more data about CRNX stock on TipRanks’ Stock Analysis page.